Gifari, Muhammad Wildan
Unknown Affiliation

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

Artificial Intelligence toward Personalized Medicine Gifari, Muhammad Wildan; Samodro, Pugud; Kurniawan, Dhadhang Wahyu
Pharmaceutical Sciences and Research Vol. 8, No. 2
Publisher : UI Scholars Hub

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

In current medical practice when a patient feels symptoms he/she would consult the doctor. The doctor then gives medication in a one-fits-all fashion. However, recent genetics studies had shown that different genetic makeup can results in different effects on medication, so the medication should be customed for every individual. The main idea of “personalized medicine” is to provide the right intervention including medication to the right patient at the right time and dose. With this approach, the medication paradigm would shift from curative to preventive. The rise of personalized medicine had been possible because the information from ever-increasing biomolecular (proteomics, genomics, and other omics) and health-related data are successfully “mined” by Artificial Intelligence (AI) tools. In this paper, we proposed that AI systems toward personalized medicine must have acceptable performance, be readily interpretable by the clinical community, and be validated in a large cohort. We examined a few landmark papers with the keyword “AI for personalized medicine application”; 1) automatic image-based patient classification, 2) automatic gene-based cancer classification, and 3) automatic health-record heart failure with preserved ejection fraction patient phenotyping. All the examples are evaluated by their performance, interpretability, and clinical validity. From the analysis, we concluded that AI for personalized medicine could benefit by five factors: (1) standardization and pooling of genetics and health data, nationally and internationally, (2) the use of multi-modalities data, (3) disease specialist to guide the development of AI model, (4) investigation of AI-finding by clinical community, and (5) follow-up of AI-finding by the large clinical trial.
Artificial Intelligence for Detecting Non-alcoholic Steatohepatitis (NASH) Gifari, Muhammad Wildan; Ramadhani, Yogi; Kurniawan, Dhadhang Wahyu
Pharmaceutical Sciences and Research
Publisher : UI Scholars Hub

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Non-alcoholic steatohepatitis (NASH), an inflammatory disease of the liver, has recently raised concern among healthcare professionals worldwide due to its asymptomatic features, making early diagnosis challenging. If left unnoticed, NASH often progresses to lethal diseases such as liver fibrosis or hepatocellular carcinoma. Recent developments in the field of artificial intelligence (AI) might facilitate the early diagnosis of NASH in a more efficient manner, forming a promising strategy to diagnose patients. In simple terms, AI is any machine that is capable of human-level intelligence, including visual perception, speech recognition, or decision making. A subclass of AI, which particularly deals with knowledge-based systems to find a relationship between different datasets, is called machine learning (ML). ML is based on the capability of a system to define or learn a relationship between the input and output data and then apply the learned relationship to any future datasets with a similar structure. The capability to maintain and analyze large datasets and aid in the prediction of outcomes makes ML particularly interesting for the application in NASH by, for instance, analyzing image data from patients, using biomarkers to predict clinical disease progression or by determining the efficacy of applied therapeutics. In this review, we will highlight the recent developments in the AI-based diagnosis and treatment of liver diseases. First, we provide a brief introduction to AI and ML before generalizing the use of AI in the diagnosis and treatment of different liver diseases. Then, we will specifically elaborate on the use of AI in the detection of NASH and its precursor, non-alcoholic fatty liver disease (NAFLD), focusing on the prediction and diagnosis of NASH and NAFLD as well as on the automation of imaging processes. Finally, we will highlight the clinical importance of AI in the detection of NASH before concluding with the future challenges for the application of AI in the field of NASH detection and treatment.